Download Pancreatic Cancer: Pathogenesis, Diagnosis, and Treatment PDF

TitlePancreatic Cancer: Pathogenesis, Diagnosis, and Treatment
Author
LanguageEnglish
File Size22.5 MB
Total Pages347
Document Text Contents
Page 1

Pancreatic Cancer

Page 2

Pancreatic Cancer
Pathogenesis, Diagnosis, and Treatment

Edited by

Howard A. Reber, M D
UCLA School of Medicine,

Los Angeles, CA

Springer Science+Business Media, LLC

Page 173

168 Baker

27. Hommeyer SC, Freeny PC, and Crabo LG. Carcinoma of the head of the pancreas: Evalu-
ation of the pancreaticoduodenal veins with dynamic CT-potential for improved accuracy
in staging. Radiology 1995; 196:-223-238.

28. Ward EM, Stephens DH, and Sheedy PF. Computed tomographic characteristics of pan-
creatic carcinoma: an analysis of 100 cases. RadioGraphies 1983; 3:547-565.

29. Lu DS, Vedantham S, Krasy RM, Kadell BM, Berger W, and Reber HA. Two-phase heli-
cal CT of pancreatic tumors: pancreatic versus hepatic phase enhancement of tumor, pan-
creas and vascular structures. Radiology 1996; 199:697-701.

30. Choi BI, Chung MJ, Han JK, and Han MC. Spiral CT in the evaluation of pancreatic ade-
nocarcinoma: relative value of arterial- and portal venous-phase scanning. Radiology 1995;
197(P):245.

31. Fishman E, Wyatt SH, Ney DR, Kuhlman IE, and Siegelman SS. Spiral CT of the pancreas
with multiplanar display. AIR 1992; 159: 1209-1215.

32. Rubin GD, Dake MD, Napel SA, McDonnell CH, and Jeffrey RB. Three-dimensional spi-
ral CT angiography of the abdomen: initial clinical experience. Radiology 1993;
186:147-152.

33. Winter TC, Freeny PC, Nghiem HV, Hommeyer SC, Barr D, Croghan AM, et aI. Hepatic
arterial anatomy in transplantation candidates: evaluation with three-dimensional CT arte-
riography. Radiology 1995; 195:363-370.

34. Cuesta MA, Meijer S, Borgstein PJ, Mulder LS, and Sikkenk AC. Laparoscopic ultra-
sonography for hepatobiliary and pancreatic malignancy. Br J Surg 1993; 80:1571-1574.

35. John TG, Greig JD, Crosbie JL, Miles WF, and Garden OJ. Superior staging of liver tu-
mors with laparoscopy and laparoscopic ultrasound. Ann Surg 1994; 220:711-719.

36. John TG, Greig JD, Carter DC, and Garden OJ. Carcinoma of the pancreatic head and pe-
riampullary region: tumor staging with laparoscopy and laparoscopic ultrasonography. Ann
Surg 1995; 221:156-164.

37. Alvarez C, Livingston EH, Ashley SW, Schwarz M, and Reber HA. Cost-benefit analysis
of the work-up for pancreatic cancer. Am J Surg 1993; 165:53-60.

38. Mitchell DG, Vinitski S, Saponaro S, Tasciyan T, Burk DL, and Rifkin MD. Liver and pan-
creas: improved spin-echo Tl contrast by shorter echo time and fat suppression at 1.5 T.
Radiology 1991; 178:67-71.

39. Semelka RC, Kroeker MA, Shoenut JP, Kroeker R, Yaffe CS, and Micflikier AB. Pancre-
atic disease: Prospective comparison of CT, ERCP, and 1.5-T MR imaging with dynamic
gadolinium enhancement and fat suppression. Radiology 1991; 181:785-791.

40. Vellet AD, Romano W, Bach DB, Passi RB, Taves DH, and Munk PL. Adenocarcinoma
of the pancreatic ducts: comparative evaluation with CT and MR imaging of 1.5 T. Radi-
ology 1992; 183:87-95.

41. Gehl HB, Vorwerk D, Klose KC, and Gunther RW. Pancreatic enhancement after low-dose
infusion of Mn-DPDP. Radiology 1991; 180:337-339.

42. Mitchell DG, Shapiro M, Schurict A, Barbot D, and Rosato FR. Pancreatic disease; find-
ings of state-of-the-art MR images. AJR 1992; 159:533-538.

43. Semelka RC and Ascher SM. MR imaging of the pancreas. Radiology 1993; 188:593-602.
44. Gehl HB, Urhahn R, Bohndorf K, Klever P, Hauptmann S, Lodemann KP, et aI. Mn-DPDP
in MR imaging of pancreatic adenocarcinoma: initial clinical experience. Radiology 1993;
186:795-798.

45. Toshifumi G, Matsui 0, Kadoya M, Yoshikawa J, Miyayama S, Takashima T, et aI. Small
pancreatic adenocarcinomas: efficacy ofMR imaging with fat suppression and gadolinium
enhancement. Radiology 1994; 193:683-688.

46. Megibow AJ, Zhou XH, Rotterdam H, Francis IR, Zerhouni EA, Balfe DM, et aI. Pancre-
atic adenocarcinoma: CT versus MR imaging in the evaluation of resectability-report of
the Radiology Diagnostic Oncology Group. Radiology 1995; 195:327-332.

Page 174

Radiologic Techniques 169

47. McFarland EG, Kaufman JA, Saini S, Halpern EF, Lu DSK, Waltman AC, and Warshaw
AL. Preoperative staging of cancer of the pancreas: value of MR angiography vs. conven-
tional angiography in detecting portal venous invasion. AJR 1996; 166:37-43.

48. Campbell JP and Wilson SR. Pancreatic neoplasms: How useful is evaluation with US? Ra-
diology 1988; 167:341-344.

49. Bares R, Klever P, Hauptmann S, Hellwig D, Fass J, Cremerius U, et al. F-18 fluo-
rodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of
pancreatic cancer. Radiology 1994; 192:79-86.

50. Stollfuss JC, Glatting G, Friess H, Kocher F, Beger HG, and Reske SN. 2-(fluorine-18)-
fluoro-2-deoxy-o-glucose PET in detection of pancreatic cancer: value of quantitative im-
age interpretation. Radiology 1995; 195:339-344.

51. Inokuma T, Tamaki N, Torizuka T, Magata Y, Fuji M, Yonekura Y, et al. Evaluation of
pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: com-
parison with CT and US. Radiology 1995; 195:345-352.

52. Kocjan G, Rode J, and Lees WR. Percutaneous fine needle aspiration cytology of the pan-
creas: advantages and pitfalls. J Clin Pathol 1989; 42:341-347.

53. AI-Kaisi N and Siegler EE. Fine needle aspiration cytology of the pancreas. Acta Cyto11989;
33:145-152.

54. Athlin L, Blind PJ, and Angstrom T. Fine-needle aspiration biopsy of pancreatic masses.
Acta Chir Scand 1990; 156:91-94.

55. Parsons L and Palmer CH. How accurate is fine-needle biopsy in malignant neoplasia of
the pancreas? Arch Surg 1989; 124:681-683.

56. Brandt KR, Charboneau JW, Stephens DH, Welch TJ, and Goellner JR. CT and US guided
biopsy of the pancreas. Radiology 1993; 187:99-104.

57. Ferrucci JT, Wittenberg J, Margolies MN, and Carey RW. Malignant seeding of the tract
after thin-needle aspiration biopsy. Radiology 1979; 130:345-346.

58. Rashleigh-Belcher HJ, Russell RC, and Lees WR. Cutaneous seeding of pancreatic carci-
noma by fine-needle aspiration biopsy. Brit J Radio11986; 59: 183-185.

59. Weiss SM, Skibber JM, Mohiuddin M, and Rosato FE. Rapid intra-abdominal spread of
pancreatic cancer. Arch 1985; 120:415-416.

60. Balen FG, Little A, Smith AC, Theis BA, Abrams KR, Houghton J, et al. Biopsy of inop-
erable pancreatic tumors does not adversely influence patient survival time. Radiology 1994;
193:753-755.

61. Lillemoe K. Current management of pancreatic carcinoma. Ann Surg 1995; 221: 133-148.
62. Stephens DH. Pancreatic adenocarcinoma: editorial commentary. Abdom Imaging 1996;
21:207-210.

Page 346

346

R

Radiation sensitivity
etiologic factors, 281

Radiation therapy, 281-292
adjuvant treatment, 288-290
altered fractionation schedules, 286
chemotherapy, 273, 274
intraoperative, 283-286
islet cell cancer, 290, 291
QOL, 333, 334

Radiation Therapy Oncology Group (RTOG)
chemoradiation, 289

Radiology Diagnostic Oncology Group
study

CT vs MRI, 163
RAF-l,24
Raf-1/MAP kinase pathway, 11
ras-GTP,24
Rats
azaserine-induced carcinoma, 61, 62

Regional pancreatectomy, 221
vs standard pancreaticoduodenectomy,

186, 187
Replication error phenotype (RER), 11, 12
Replication errors (RER+), 84
Resectable pancreatic tumor
defined, 159, 160

Residual cancer
pancreaticoduodenectomy, 209

Retroperitoneal vascular dissection, 190-193
Retroviral vectors, 297, 298
Rhabdomyosarcoma, 95
Rotterdam Symptom Checklist, 321, 326
Roux-en-Y jejunostomy, 254

S

Scintigraphy, 159, 164, 165
cost, 165

Serial analysis of gene expression (SAGE),
127-129

Short Form 36, 321
Single-strand conformation polymorphism

(SSCP)
p53 mutations, 122-124

Somatic genetic therapy, 295
technology, 296-300

Somatostatin, 65
Son-of-sevenless (SOS), 24
SPAN-1,145
vs CA 19-9, 145, 146

Index

Sp~~CT, 158, 159, 161, 162, 176, 186, 191
Sporadic pancreatic cancer
definition, 12

Standard pancreaticoduodenectomy
vs regional pancreatectomy, 186, 187

Stent occlusion, 244
plastic endoprosthesis, 238

Stool samples
K-ras mutations, 120, 121
p53 mutations, 124

Strecker stent, 239
Streptozocin, 271, 287
Superior mesenteric artery (SMA), 182,

185-190,192, 193
Superior mesenteric-portal vein (SMPV),

182,185-187, 190, 191
Surgical resection, 181-196
malignant obstructive jaundice, 244--246
QOL, 331, 332
quality of life, 326

Swiss Group for Clinical Cancer Research
(SAKK),325

Syrian golden hamsters, 53

T

Tamoxifen (Tam), 86, 89, 90, 271
T cell suppressor factor (TcSF), 92
Testosterone, 65
Testosterone:dihydrotestosterone ratio

(T:DHT), 148, 149
TGF-a,35
TGF-B
cancer etiopathogenesis, 95, 96
cancer growth regulation, 80-96
growth inhibition, 79, 80

TGF-Bl
breast cancer, 89-94
colon cancer, 82, 83
endometrial carcinoma, 86-89
gastric cancer, 84--86
gliomas, 92-94
osteosarcomas, 94, 95

TGF-B2
breast cancer, 89-94
endometrial carcinoma, 86-89
gastric cancer, 84--86
gliomas, 92-94
osteosarcomas, 94, 95

TGF-B3
breast cancer, 89-94
endometrial carcinoma, 86-89

Page 347

Index

gastric cancer, 84-86
osteosarcomas, 94, 95

TGF-B antisense, 93, 94
TGF-B receptors (TBR), 45
TGF-B receptor type I, 45, 75, 80, 81, 90, 91
TGF-B receptor type II, 45, 75, 80, 90, 91
TGF-B receptor type III, 45, 75, 81
Tissue polypeptide antigen (TPA), 148, 149
Tissue polypeptide specific antigen (TPS),

148, 149
Total pancreatectomy (TP), 223
resection rate, 216
survival rate, 216-220

TP53, 300, 301
Transabdominal ultrasound, 157, 163, 164
Transforming growth factor alpha (TGF-a),

22-24
Transfonning growth factor-B (TGF-B), 71-96
activation, 74
cell growth, 77-80
chronic pancreatitis, 42-46
functions, 73, 74
oncogenesis, 71, 72
receptor binding, 75-77
regulation, 75-77
structure, 73, 74

Transgenic mouse model, 60
Trypsin inhibitors, 64, 65
Tumor-associated antigens (TAAs), 137-150
Tumorigenesis, 3
Tumor markers
pancreatic cancer, 137, 138

Tumor resectability
assessment, 181-185
extended radical Whipple resection, 204-206

347

Tumor-suppressor gene function
replacement, 300, 301

Tumor-supressor genes, 5-9

u
Ubiquitin-proteasome pathway, 80
Ultrasound, 157, 158, 163, 164,236
Ultrasound-guided percutaneous biopsy, 165
cost, 165

Union Internationale Contre Le Cancer
(UICC) staging classification, 204

vs Japanese classification, 226
Urine
p53 mutations, 124

v
Vaccina virus, 298
Vascular involvement
CT vs angiographic detection, 160, 161

Vincristine, 273
Viral vectors, 297, 298
Vomiting, 322

W

VVAFI, 123, 124,301
VVallstent, 241, 248
VVeight loss, 323
VVestern experience
pancreaticoduodenectomy, 195, 196

VVhipple resection, 201-211, 326, 331, 332
VVide-field irradiation, 287
VVodd VVide VVeb
National Familial Pancreatic Tumor

Registry, 127

Similer Documents